At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02137 BRII-B
Trading 01-22 14:54:22
1.530
+0.010
+0.66%
High1.560
Low1.530
Vol316.00K
Open1.560
D1 Closing1.520
Amplitude1.97%
Mkt Cap1.10B
Tradable Cap1.10B
Total Shares721.00M
T/O487.97K
T/O Rate0.04%
Tradable Shares721.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BRIEF-Brii Biosciences And OpenBench Announce AI-Driven Collaboration For Proprietary Technology Platform
Brii Biosciences Ltd is a biotechnology company principally focused on developing therapies for infectious diseases and central nervous system diseases. The Company's HBV portfolio products include the proprietary therapeutic vaccine BRII-179, the siRNA BRII-835 (elebsiran), and the neutralizing antibody BRII-877 (tobevibart). The Company owns a broad pipeline of multiple innovative drug candidates that focus on infectious diseases and central nervous system diseases. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The Company mainly conducts its businesses in China market.